Chief Technical Officer, Sonoma Bio
Biography
An accomplished operations executive with 30 years of experience in the biotechnology and medical device industries and an extensive track record in leading operations from early clinical trials through commercialization of innovative technologies ranging from recombinant protein/device combinations to the first active immune cell therapy, Provenge. She most recently served as interim Chief Executive Officer at Ziopharm Oncology (Alaunos), where she also sat on the company’s Board of Directors. Prior to Ziopharm, Hagen co-founded Vineti, a supply chain software company for cell and gene therapy, early on serving as the company’s Chief Strategy Officer. Before that, she served as interim Chief Commercial Officer at ZappRx, Global Chief Operating Officer at Sotio a.s., Senior Vice President Operations at Dendreon and Project Manager at Immunex. She has been responsible for operations including manufacturing, supply chain operations, and patient operations through clinical trials and commercialization. She sits on the boards of Obsidian Therapeutics and Vericel Corporation
Session Abstract – PMWC 2023 Silicon Valley
Track 1 - January 26 9.00 A.M.-4.30 P.M.
Track Chair: Sharon Benzeno, Adaptive Biotechnologies
- PMWC 2023 Luminary Award Ceremony
Honoree: Bruce Levine, University of Pennsylvania
- Advance and Optimize Cell Therapies in Oncology (PANEL)
Chair: Sharon Benzeno, Adaptive Biotechnologies
- Ira Mellman, Genenetch
- Mark Selby, Walking Fish Therapeutics
- Sneha Ramakrishna, Stanford
- Loïc VINCENT, Affini-T Therapeutics
- Nick Haining, Arsenal
- Warner Biddle, Kite - Pioneering Cell Therapies in the Treatment of Autoimmune Disorders (PANEL)
Chair: Carl June, UPenn
- Lenny Dragone, Sonoma
- James Chung, Kyverna
- David Chang, Cabaletta
- Cristina Musselli, Abata Therapeutics - Innovations in Cell Therapy Manufacturing (PANEL)
Chair: Bruce Levine, University of Pennsylvania
- Chris Holt, BMS
- Heidi Hagen, Sonoma Bio
- Rahul Singhvi, Resilience
- Snehal Patel, Sana Biotechnology - Patentability of Immunotherapies - Latest Developments
- Janet Xiao, Morrison & Foerster LLP
- Investing in Gene-Modified Cell Therapies
Chair: Karen Tkach Tuzman, BioCentury Inc.
- Robert Lin, UPMC
- Yvonne Yamanaka, venBio
- Abraham Bassan, Samsara Capital
- Brian Daniels, 5am Ventures
- Leveraging Data Sets to Inform Future Drug Discovery and Development (PANEL)
Chair: Jason Coloma, Maze Therapeutics
- Peter DiLaura, Sonoma Bio
- Nick Haining, Arsenal
- Kwame Okrah, Parker Institute
- Dan Kirouac, Notch Therapeutics
